Highlights
Vol. 9 No. 1 (2017): Review, Original Articles, Case Reports
WHO HAS THERAPY-RELATED AML?
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: January 11, 2017
Accepted: February 23, 2017
Accepted: February 23, 2017
3729
Views
4244
Downloads
734
HTML
Authors
Therapy-related leukemia or therapy-related myeloid neoplasm are widely-used terms to designate leukemia developing in persons who previously received anti-cancer therapy (for example, see references 1, 2), especially if the prior anti-cancer therapy included drugs such as alkylators, DNA-intercalators, topoisomerase-2-inhibitors, purines and/or ionizing radiations. Sometimes specific genes such as AML1, EVI1, NRAS or MLL are mutated by therapy or gene variants are produced which activate mutagens or interfere with DNA repair, such FANC, NQ01 or AML2. 3-5 But how can we know if AML in someone is a therapy-related?
Keywords: Therapy-related leukemia; alkylators; ionizing radiations; Topoisomerase Inhibitors; DNA Repair
Downloads
Download data is not yet available.
Citations
How to Cite
“WHO HAS THERAPY-RELATED AML?” (2017) Mediterranean Journal of Hematology and Infectious Diseases, 9(1), p. e2017025. doi:10.4084/mjhid.2017.025.
